NCT05291286 - BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2024

Conditions

Neuropathy;PeripheralChemotherapy-induced Peripheral Neuropathy

Interventions

DRUG

BXQ-350

BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion

OTHER

Placebo

Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion

Trial Locations (3)

37232

Vanderbilt University Medical Center, Nashville

43210

The Ohio State Unviersity, Columbus

45212

CTI Clinical Research Center, Cincinnati